Arbutus Biopharma (ABUS) Competitors $3.46 -0.09 (-2.54%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends ABUS vs. DYN, CPRX, HCM, PTGX, AGIO, IOVA, AMRX, LBPH, NAMS, and IDYAShould you be buying Arbutus Biopharma stock or one of its competitors? The main competitors of Arbutus Biopharma include Dyne Therapeutics (DYN), Catalyst Pharmaceuticals (CPRX), HUTCHMED (HCM), Protagonist Therapeutics (PTGX), Agios Pharmaceuticals (AGIO), Iovance Biotherapeutics (IOVA), Amneal Pharmaceuticals (AMRX), Longboard Pharmaceuticals (LBPH), NewAmsterdam Pharma (NAMS), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry. Arbutus Biopharma vs. Dyne Therapeutics Catalyst Pharmaceuticals HUTCHMED Protagonist Therapeutics Agios Pharmaceuticals Iovance Biotherapeutics Amneal Pharmaceuticals Longboard Pharmaceuticals NewAmsterdam Pharma IDEAYA Biosciences Arbutus Biopharma (NASDAQ:ABUS) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their community ranking, media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability. Do institutionals & insiders hold more shares of ABUS or DYN? 43.8% of Arbutus Biopharma shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 4.0% of Arbutus Biopharma shares are held by insiders. Comparatively, 20.8% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is ABUS or DYN more profitable? Dyne Therapeutics has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -1,137.65%. Dyne Therapeutics' return on equity of -57.46% beat Arbutus Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Arbutus Biopharma-1,137.65% -68.18% -51.55% Dyne Therapeutics N/A -57.46%-51.62% Does the media prefer ABUS or DYN? In the previous week, Dyne Therapeutics had 12 more articles in the media than Arbutus Biopharma. MarketBeat recorded 14 mentions for Dyne Therapeutics and 2 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 1.51 beat Dyne Therapeutics' score of 0.64 indicating that Arbutus Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Dyne Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has stronger valuation & earnings, ABUS or DYN? Arbutus Biopharma has higher revenue and earnings than Dyne Therapeutics. Arbutus Biopharma is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArbutus Biopharma$6.74M97.25-$72.85M-$0.43-8.05Dyne TherapeuticsN/AN/A-$235.94M-$3.56-7.35 Which has more risk & volatility, ABUS or DYN? Arbutus Biopharma has a beta of 1.84, indicating that its stock price is 84% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Does the MarketBeat Community prefer ABUS or DYN? Arbutus Biopharma received 401 more outperform votes than Dyne Therapeutics when rated by MarketBeat users. However, 73.33% of users gave Dyne Therapeutics an outperform vote while only 71.03% of users gave Arbutus Biopharma an outperform vote. CompanyUnderperformOutperformArbutus BiopharmaOutperform Votes43471.03% Underperform Votes17728.97% Dyne TherapeuticsOutperform Votes3373.33% Underperform Votes1226.67% Do analysts recommend ABUS or DYN? Arbutus Biopharma presently has a consensus price target of $5.50, indicating a potential upside of 58.96%. Dyne Therapeutics has a consensus price target of $50.42, indicating a potential upside of 92.72%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than Arbutus Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Arbutus Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Dyne Therapeutics 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.08 SummaryDyne Therapeutics beats Arbutus Biopharma on 11 of the 18 factors compared between the two stocks. Ad Porter & CompanyMusk threatens Liberal’s fake “energy crisis”Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ABUS vs. The Competition Export to ExcelMetricArbutus BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$655.64M$6.87B$5.20B$9.31BDividend YieldN/A3.06%4.80%4.06%P/E Ratio-8.0510.75128.1117.53Price / Sales97.25287.461,260.62139.54Price / CashN/A56.6541.3637.95Price / Book5.495.394.894.92Net Income-$72.85M$152.04M$119.92M$225.78M7 Day Performance-4.95%-4.33%16.64%-1.56%1 Month Performance-1.70%2.79%16.35%6.68%1 Year Performance57.99%17.30%35.47%22.48% Arbutus Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ABUSArbutus Biopharma2.4837 of 5 stars$3.46-2.5%$5.50+59.0%+54.5%$655.64M$6.74M-8.0573Positive NewsDYNDyne Therapeutics3.1855 of 5 stars$26.12+1.5%$50.42+93.0%+106.0%$2.66BN/A-7.23100CPRXCatalyst Pharmaceuticals4.6439 of 5 stars$21.85+2.2%$31.14+42.5%+53.5%$2.61B$398.20M18.12167Short Interest ↑HCMHUTCHMED2.5385 of 5 stars$14.91-4.3%$19.00+27.4%-23.1%$2.60B$838M0.001,988PTGXProtagonist Therapeutics3.653 of 5 stars$41.65+1.4%$53.78+29.1%+93.1%$2.48B$60M15.44125Positive NewsAGIOAgios Pharmaceuticals4.355 of 5 stars$43.44+11.5%$56.33+29.7%+80.6%$2.48B$32.87M3.73390Analyst RevisionIOVAIovance Biotherapeutics4.0758 of 5 stars$7.92+1.1%$22.33+182.0%+0.4%$2.41B$1.19M-5.25500Short Interest ↑AMRXAmneal Pharmaceuticals2.193 of 5 stars$7.74-1.1%$10.00+29.2%+55.5%$2.40B$2.39B-11.517,700Positive NewsLBPHLongboard Pharmaceuticals1.2893 of 5 stars$59.98+0.0%$59.56-0.7%+1,094.8%$2.34BN/A-26.9020NAMSNewAmsterdam Pharma2.5475 of 5 stars$24.60-0.4%$36.20+47.2%+147.8%$2.27B$33.59M0.0057Insider TradeIDYAIDEAYA Biosciences4.3729 of 5 stars$25.86+2.7%$53.67+107.5%-24.9%$2.24B$3.92M-10.8180Analyst ForecastShort Interest ↓ Related Companies and Tools Related Companies DYN Alternatives CPRX Alternatives HCM Alternatives PTGX Alternatives AGIO Alternatives IOVA Alternatives AMRX Alternatives LBPH Alternatives NAMS Alternatives IDYA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ABUS) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABUS Stock Alerts